Genetically engineered Sertoli cells are able to survive allogeneic transplantation

Gene Therapy

Volumn 11, Issue 8, 2004, Pages 694-700

  Dufour, J M ^a   Hemendinger, R ^b   Halberstadt, C R ^b   Gores, P ^b   Emerich, D F ^c   Korbutt, G S ^a   Rojotte, R V ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CAROLINAS MEDICAL CENTER   (United States)

^c Sertoli Technologies Incorporated   (United States)

Author keywords

GFP; Sertoli cell; Transplantation

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; DOPAMINE; GREEN FLUORESCENT PROTEIN; INSULIN; TRANSCRIPTION FACTOR GATA 4;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENETIC ENGINEERING; IMMUNITY; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; SCID MOUSE; SERTOLI CELL; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT;

ANIMALS; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; SERTOLI CELLS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

MUS MUSCULUS;

EID: 1942537803     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302218     Document Type: Article

References (35)

1. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977; 25: 1-54.
2. Gores PF et al. Long-term survival of intratesticular porcine islets in non-immunosuppressed beagles. Transplantation 2003; 75: 613-618.
3. Selawry HP. Islet transplantation to immunoprivileged sites. In: Lanza RP, Chick WL (eds) Pancreatic Islet Transplantation Vol. II Immunomodulation of Pancreatic Islets. R.G. Landes Co.: Austin, TX, 1994, pp 75-86.
4. Streinlein JW. Unraveling immune privilege. Science 1995; 270: 1158-1159.
5. Cameron DF, Whittington K, Schultz RE, Selawry HP. Successful islet/abdominal testis transplantation does not require Leydig cells. Transplantation 1990; 50: 649-653.
6. Selawry HP, Whittington KB. Prolonged intratesticular islet allograft survival is not dependent on local stereoidogenesis. Horm Metab Res 1988; 20: 562-565.
7. Whitmore III WF, Karsh L, Gittes RF. The role of germinal epithelium and spermatogenesis in the privileged survival of intratesticular grafts. J Urol 1985; 134: 782-786.
8. Bellgrau D et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
9. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317-322.
10. Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 1993; 2: 123-129.
11. Yang H, Wright Jr JR. Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Transplantation 1999; 67: 815-820.
12. Dufour JM et al. Long-term survival of neonatal porcine Sertoli cells in non-immunosuppressed rats. Xenotransplantation 2003; 10: 577-586.
13. Saporta S, Cameron DF, Borlongan CV, Sanberg PR. Survival of rat and porcine Sertoli cell transplants in the rat striatum without cyclosporine-A inummosuppression. Exp Neurol 1997; 146: 299-304.
14. Dufour JM, Rajotte RV, Kin T, Korbutt GS. Immunoprotection of rat islet xenografts by co-transplantation with Sertoli cells and a single injection of antilymphocyte serum. Transplantation 2003; 75: 1594-1596.
15. Kin T, Rajotte RV, Dufour JM, Korbutt GS. Development of an immunoprivileged site to prolong allograft survival. Cell Transplant 2002; 11: 547-552.
16. Korbutt GS et al. Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice. Diabetologia 2000; 43: 474-480.
17. Sanberg PR, Borlongan CV, Saporta S, Cameron DF. Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nat Biotech 1996; 14: 1692-1695.
18. Suarez-Pinzon W et al. Testicular Sertoli cells protect islet β-cells from autoimmune destruction in NOD mice by a transforming growth fa ctor-β1-dependent mechanism. Diabetes 2000; 49: 1810-1818.
19. Willing AE et al. Sertoli cells decrease microglial response and increase engraftment of human hNT neurons in the hemiparkinsonian rat striatum. Brain Res Bull 1999; 48: 441-444.
20. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357.
21. Romano G, Micheli P, Pacilio C, Giordano A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000; 18: 19-39.
22. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy Nat Rev Gentet 2003; 4: 346-358.
23. Shapiro AMJ et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regime. N Engl J Med 2000; 343: 230-238.
24. Dufour JM, Rajotte RV, Korbutt GS. Development of an in vivo model to study testicular morphogenesis. J Androl 2002; 23: 635-644.
25. Chakraborty J. Conditions adversely affecting Sertoli cells. in: Russell LD, Griswold MD (eds) The Sertoli Cell. Cache River Press: Clearwater, FL, 1993, pp 578-579.
26. Stripecke R et al. Immune response to green fluorescent protein: implications for gene therapy. Gene Therapy 1999; 6: 1305-1312.
27. Marshall E. Gene therapy on trial. Science 2000; 288: 951-957.
28. Giraldo P. Montoliu L. Size matters: use of YACs, BACs and PACs in transgenic animals. Transgenic Res 2001; 10: 83-103.
29. Papaioannou VE. The coming of age of the transgenic era. Int J Dev Biol 1998; 42: 841-846.
30. Houdebine LM. The production of pharmaceutical proteins from the milk of transgenic animals. Reprod Nutr Dev 1995; 35: 609-617.
31. Illmensee K. Biotechnology in reproductive medicine. Differentiation 2002; 69: 167-173.
32. Lai L et al. Transgenic pig expressing the enhanced green fluorescent protein produced by nuclear transfer using colchicine-treated fibroblasts as donor cells. Mol Reprod Dev 2002; 62: 300-306.
33. Levy JH, Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 2001; 27: 405-416.
34. Pollock DP et al. Transgenic milk as a method for the production recombinant antibodies. J Immunol Methods 1999; 231: 147-157.
35. Hadjantonakis AK et al. Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech Dev 1998; 76: 79-90.